Niagen Bioscience, Inc. (NAGE) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for standing by, and welcome to Niagen Biosciences, Inc.' 's first quarter of 2025 earnings conference call. My name is Kayla, and I will be the conference operator today. At this time, all participants are in a listen-only mode, and as a reminder, this conference call is being recorded. This afternoon, Niagen Biosciences issued a news release announcing the company's financial results for the first quarter of 2025. If you have not reviewed this information, both are available within the Investor Relations section of Niagen Bioscience's website at www.niagensbioscience.com. I would now like to turn the conference call over to Wesley Yu, Vice President of Finance. Please go ahead, Mr. Yu. Thank you. Good afternoon, and welcome to Niagen Bioscience's first quarter of 2025 conference call. With us today are Nijen Biosciences Chief Executive Officer Rob Fried, Chief Financial Officer Ozan Tamir, and Senior Vice President of Scientific and Regulatory Affairs, Dr. Andrew Hsiao. Dr. Hsiao will join the call for Q&A. Today's conference call may include forward-looking statements, including statements related to the company's research and development and clinical trial plans and the timing and results of such trials. The timing of future regulatory filings, the expansion of the sale of nitrogen products and ingredients in new markets, business development opportunities, future financial results, cash needs, operating performance, investor interests, and business prospects and opportunities, as well as anticipated results of operations. Forward-looking statements represent only the company's estimates on the date of this conference call and are not intended to give any assurance as to actual future results. Because forward-looking statements rel...